Scandinavian Simvastatin Survival Study Group (4S)

• All cause mortality decreased from 11.5% to 8.2%

• Coronary deaths decreased from 8.5% to 5.0%

• Acute MI decreased from 12.1% to 7.4%

• Incidence of CABG or PTCA decreased from 17.2% to 11.3%

Previous slide

Next slide

Back to first slide

View graphic version